Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 4/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.54 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7827157 | 0.88 | AKR1B1 (0.67) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| SCHEMBL9890643 | 0.87 | CXCL8 (0.54) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| SCHEMBL28933632 | 0.85 | DPP4 (0.52) | CXCL8DPP4TTRPTGS2AKR1B10 | |
| SCHEMBL10714790 | 0.84 | PTGS2 (0.51) | CXCL8DPP4TTRPTGS2AKR1B10 | |
| SCHEMBL194831 | 0.84 | CXCL8 (0.65) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| SCHEMBL29933245 | 0.84 | CXCL8 (0.65) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| SCHEMBL2394862 | 0.83 | DPP4 (0.58) | CXCL8DPP4RAB9ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2529217 | 0.82 | CXCL8 (0.62) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| SCHEMBL11226769 | 0.82 | CXCL8 (0.62) | CXCL8TTRPTGS2AKR1B10UGT1A9 | |
| Bromide SCHEMBL8119525 | 0.82 | CXCL8 (0.62) | CXCL8TTRPTGS2AKR1B10UGT1A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791693-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2016-04-13 | — | — | CN | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CXCL8 3300/4885DPP4 3177/4885TTR 3467/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CXCL8 3300/4885DPP4 3177/4885TTR 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.